公开(公告)号：EP2323647B1

公开(公告)日：2014-09-10

申请号：EP09777388.1

申请日：2009-07-23

申请人： SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. ,  Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio ,  CACCIA, Maria, Giovanna

IPC分类号： A61K31/23 ,  A61P9/06

CPC分类号： A61K31/23

公开(公告)号：EP1128822B1

公开(公告)日：2005-10-12

申请号：EP99956311.7

申请日：1999-11-05

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A61K31/22 ,  A61K31/205 ,  A61K35/78 ,  A23L1/302 ,  A23L1/304 ,  A61P9/10 ,  A61P37/08 ,  A61P29/00

CPC分类号： A61K31/35 ,  A23L33/105 ,  A23L33/15 ,  A23L33/165 ,  A23V2002/00 ,  A61K31/70 ,  A61K2300/00 ,  A23V2250/0612 ,  A23V2250/2116 ,  A23V2250/70 ,  A23V2250/211 ,  A23V2250/1612 ,  A23V2250/156 ,  A23V2250/0622 ,  A23V2250/0632 ,  A23V2250/708 ,  A23V2250/314 ,  A23V2250/712

摘要： A composition is disclosed which comprises as characterizing active ingredients propionyl L-carnitine and a flavonoid, typically quercetin or its 3-rutinoside, rutin, for the prevention and/or therapeutic treatment of various alterations and pathological states induced by free radicals and by thrombotic or atherosclerotic abnormalities, that may take the form of a dietary supplement, dietetic support or of an actual medicine.

公开(公告)号：EP0998276B1

公开(公告)日：2005-03-09

申请号：EP98932502.2

申请日：1998-07-08

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A61K31/205

CPC分类号： A61K31/221 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/2059 ,  A61K31/205 ,  A61K47/02 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26

摘要： A therapeutical method for the treatment of Attention-Deficit/Hyperactive Disorder (ADHD) is disclosed which comprises administering to a child in need thereof L-carnitine or an alkanoyl L-carnitine or a pharmacologically acceptable salt thereof.

公开(公告)号：EP0999832B1

公开(公告)日：2004-09-29

申请号：EP98932504.8

申请日：1998-07-09

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A61K31/205

CPC分类号： A61K31/221

摘要： The use of L-carnitine, some alkanoyl L-carnitines and the pharmacologically acceptable salts thereof is disclosed, in combination with long-chain alkanols such as polycosanols, or polycosanol-bearing natural products or extracts thereof for the prevention and treatment of diseases caused by abnormal lipid metabolism, such as atherosclerosis, hypercholesterolaemia, cardiovascular disorders and peripheral diabetic neuropathy.

公开(公告)号：EP1163207B1

公开(公告)日：2003-08-20

申请号：EP00920506.3

申请日：2000-03-16

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： C07C227/18 ,  C07C229/22

CPC分类号： C07C229/22 ,  C07C227/18

摘要： An improved process for the preparation of non-hygroscopic salts of L(-)-carnitine, in which the characterizing step comprises heating a mixture comprising L(-)-carnitine inner salt and a fumaric acid or tartaric acid.

公开(公告)号：EP1163207A1

公开(公告)日：2001-12-19

申请号：EP00920506.3

申请日：2000-03-16

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： C07C227/18 ,  C07C229/22

CPC分类号： C07C229/22 ,  C07C227/18

摘要： An improved process for the preparation of non-hygroscopic salts of L(-)-carnitine, in which the characterizing step comprises heating a mixture comprising L(-)-carnitine inner salt and a fumaric acid or tartaric acid.

公开(公告)号：EP1100589B1

公开(公告)日：2005-01-19

申请号：EP99936973.9

申请日：1999-07-27

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio ,  PISANO, Claudio ,  VESCI, Loredana

IPC分类号： A61P35/00 ,  A61K45/06 ,  A61K31/335 ,  A61K38/14 ,  A61K31/555 ,  A61K31/475

CPC分类号： A61K45/06 ,  A61K31/205 ,  A61K31/221 ,  A61K31/28 ,  A61K31/335 ,  A61K31/475 ,  A61K31/555 ,  A61K33/24 ,  A61K38/14 ,  A61K2300/00

公开(公告)号：EP1087762B1

公开(公告)日：2004-11-17

申请号：EP00922845.3

申请日：2000-04-07

申请人： Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A61K31/205 ,  A61K35/72 ,  A61P9/10

CPC分类号： A61K31/205 ,  A61K36/062 ,  A61K38/063 ,  A61K31/195 ,  A61K36/06 ,  A61K33/06 ,  A61K2300/00

摘要： A composition is disclosed useful to increase the absorption of glutathione and synergize its effects, that, depending on user's conditions, may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof; (b) glutathione or a glutathione-containing yeast; (c) a glutathione-free yeast if the component (b) consists of glutathione.

公开(公告)号：EP1196046B1

公开(公告)日：2004-04-07

申请号：EP00951844.0

申请日：2000-07-21

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A23L1/302 ,  A61K31/205

CPC分类号： A61K31/205 ,  A23L33/15 ,  A23V2002/00 ,  A61K31/66 ,  A61K2300/00 ,  A23V2250/161 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1612 ,  A23V2250/712 ,  A23V2250/314 ,  A23V2250/0612 ,  A23V2250/306 ,  A23V2250/1618 ,  A23V2250/30 ,  A23V2250/708 ,  A23V2250/211 ,  A23V2250/70 ,  A23V2250/606 ,  A23V2250/5114 ,  A23V2250/156 ,  A23V2250/0632 ,  A23V2250/0644

摘要： A composition is disclosed suitable for the prevention and/or treatment of muscular energetic deficiencies and states of asthenia for enhancing sport performances and for the treatment of states of heart fatigue, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients a combination of L-carnitine and/or at least one alkanoyl L-carnitine and creatinol-phosphate.

公开(公告)号：EP0971600B1

公开(公告)日：2003-06-04

申请号：EP98908280.5

申请日：1998-03-10

申请人： SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

发明人： CAVAZZA, Claudio

IPC分类号： A23L1/30 ,  A23L1/302

CPC分类号： A23L33/15 ,  A23L33/12 ,  A23V2002/00 ,  Y10S514/866 ,  A23V2250/702 ,  A23V2250/704 ,  A23V2250/161 ,  A23V2250/1578 ,  A23V2250/1642 ,  A23V2250/1626 ,  A23V2250/1586 ,  A23V2250/1636 ,  A23V2250/1874 ,  A23V2250/30 ,  A23V2250/0612 ,  A23V2250/0644 ,  A23V2250/70 ,  A23V2250/156 ,  A23V2250/314 ,  A23V2250/026

摘要： A medical food for diabetics is disclosed which comprises as characterizing active ingredients η-linolenic acid and at least one alkanoyl-L-carnitine, e.g. acetyl-L-carnitine and/or propionyl-L-carnitine.